TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02215473
Drug: Chlorhexidine gluconate mouth rinse
Normalized name: chlorhexidine gluconate Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
Study: NCT00811850
Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Study: NCT00811850
Drug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Normalized name: dorzolamide / timolol Ophthalmic Solution
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Study: NCT00353912
Drug: valsartan + amlodipine
Normalized name: amlodipine / valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03475381
Drug: Ivacaftor+lumacaftor
Normalized name: ivacaftor / lumacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 year follow-up after initiation of ivacaftor+lumacaftor
Study: NCT02941445
Drug: sitagliptin and metformin
Normalized name: Sitagliptin and Metformin Hydrochloride Extended Release Tablets
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02941445
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00362115
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT00362115
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT00362115
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT00362115
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT00362115
Drug: Azilsartan Medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT00362115
Drug: Olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
Study: NCT01980355
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04665895
Drug: Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: twice daily inhalation throughout the study
Study: NCT03682484
Drug: MA-0211
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02793050
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Collection of data on the clinical use of Trabectedin
Study: NCT04600089
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline infusion
Study: NCT04600089
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous ketamine infusion at a dose of 0.2 mg/kg/hr, initiated at the induction of anesthesia and continued for 48 hours postoperatively.
Study: NCT00553969
Drug: carvedilol phosphate
Normalized name: carvedilol phosphate
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
Study: NCT00553969
Drug: lisinopril
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Study: NCT00553969
Drug: carvedilol phosphate and lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
Study: NCT00622206
Drug: ritonavir and saquinavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
Study: NCT00835354
Drug: Cefprozil for oral suspension 250 mg/5 mL
Normalized name: cefprozil Oral Suspension
DrugBank: Cefprozil (DB01150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 250 mg/5 mL, single-dose fasting
Study: NCT01653314
Drug: Megavec
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01653314
Drug: Glivec
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03510715
Drug: Alirocumab SAR236553 (REGN727)
DrugBank: Alirocumab (DB09302)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution for injection in pre-filled syringe,~Route of administration: subcutaneous (SC)
Study: NCT03510715
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Cholestyramine
Normalized name: Cholestyramine
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: oral suspension,~Route of administration: oral
Study: NCT03510715
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet,~Route of administration: oral
Study: NCT03510715
Drug: Omega-3 fatty acids
Normalized name: Omega-3 Fatty Acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule,~Route of administration: oral
Study: NCT00713193
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-3 mg/kg orally in a twice day divided dose for 6 months
Study: NCT00713193
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
Study: NCT06080204
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide LAR (Sandostatin® LAR, Novartis Pharmaceuticals Corporation) treatment by deep intramuscular injection at a dose of 30 mg every 28 days for 6-12 months。
Study: NCT02990702
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03181984
Drug: Hemoporfin
Normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoporfin mediated photodynamic therapy
Study: NCT01303796
Drug: Sapacitabine
Normalized name: Sapacitabine
DrugBank: Sapacitabine (DB06365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sapacitabine capsules
Study: NCT00697385
Drug: Cyclokapron
DrugBank: Cyclo(his-pro) (DB02414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (2) 500mg tablets taken by mouth every 6-8 hours
Study: NCT02457793
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib given concurrently or intermittently with GDC-0994 for 21 consecutive days followed by 7 days off.
Study: NCT02457793
Drug: GDC-0994
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0994 given for 21 consecutive days followed by 7 days off, along with concurrent or intermittent dosing of cobimetinib.
Study: NCT02401594
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
Study: NCT02401594
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Study: NCT01622972
Drug: Polyethyleneglycol
Normalized name: 2-(4-(4-((1-(107- (4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5- diiodophenoxy)-3,5-diiodophenyl)acetic acid
DrugBank: 2-(2-{2-[2-(2-{2-[2-(2-Ethoxy-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethoxy]-Ethoxy}-Ethoxy)-Ethanol, Polyethyleneglycol Peg400 (DB03556)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
Study: NCT01303796
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine intravenous
Study: NCT02290951
Drug: Odronextamab multiple dose levels
Normalized name: peanut allergenic extract
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous (IV) infusion
Study: NCT02290951
Drug: Odronextamab multiple dose levels
Normalized name: peanut allergenic extract
DrugBank: Odronextamab (DB16684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous (SC) injection
Study: NCT02757768
Drug: Mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received initial dose of 25 mg of mirabegron (oral tablet) which was increased to 50 mg after 4 weeks.
Study: NCT02757768
Drug: Tamsulosin Hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received once daily treatment with tamsulosin hydrochloride 0.4 mg (oral tablet) throughout the study.
Study: NCT01128595
Drug: Fluticasone Furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01532648
Drug: Budesonide MMX®
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral tablet taken daily in the morning after breakfast.
Study: NCT01532648
Drug: 5-ASA
Normalized name: 5-ASA
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acceptable oral 5-ASA medications to be received during the study include:~* Asacol®, Asacol® HD, Lialda®, Pentasa® (generic: mesalamine), minimum daily dose ≥2.4 grams (g)~* Azulfidine® (generic: sulfasalazine), minimum daily dose ≥4.0 g~* Dipentum® (generic: olsalazine), minimum daily dose ≥2.0 g~* Colazal®, Colazide® (generic: balsalazide), minimum daily dose ≥6.75 g
Study: NCT01857232
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5HT3-antagonist
Study: NCT01857232
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Corticosteroid
Study: NCT01857232
Drug: Fosaprepitant
Normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NK1 antagonist
Study: NCT03968042
Drug: Nerve Growth Factor
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection for 2 weeks
Study: NCT03968042
Drug: Edaravone
Normalized name: Edaravone
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous injection for 2 weeks
Study: NCT03968042
Drug: Combination of vitamin B1, B6, C, E and mecobalamine
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medications of combination of vitamin B1, B6, C, E and mecobalamine for 6 months
Study: NCT04066504
Drug: sonidegib
Normalized name: Sonidegib
DrugBank: Sonidegib (DB09143)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sonidegib 200 mg orally taken once daily (dose modifications according to the approved local country prescribing information are permitted)
Study: NCT00775671
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 5 mg by mouth daily for 12 weeks.
Study: NCT00775671
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol ER 100mg by mouth daily for 12 weeks.
Study: NCT02411851
Drug: ingenol mebutate 0.015%
Normalized name: INGENOL MEBUTATE 0.015% GEL,TOP
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
Study: NCT02723669
Drug: acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral solution
Study: NCT02776735
Drug: Sarilumab
Normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution Route of administration: Subcutaneous
Study: NCT00581100
Drug: etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.~Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period.
Study: NCT03107182
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
Study: NCT03107182
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
Study: NCT03107182
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).~Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses.
Study: NCT03107182
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
Study: NCT03107182
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
Study: NCT03107182
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
Study: NCT03107182
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
Study: NCT03107182
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
Study: NCT03107182
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
Study: NCT03107182
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
Study: NCT00216385
Drug: Gatifloxacin combined regimen
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02371889
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Max therapeutic dose of 200mg/day
Study: NCT00083681
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00083681
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00083681
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00083681
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00083681
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00083681
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02929420
Drug: Xiao Yao pills
Normalized name: Xiao mai
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
Study: NCT01644331
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
Study: NCT02852837
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
Study: NCT05058443
Drug: Denosumab 60 mg/ml [Prolia]
Normalized name: denosumab 60 MG/ML [Prolia]
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: denosumab subcutaneously every 6 months (Q6M)
Study: NCT01661595
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/day for 4 weeks
Study: NCT01661595
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day for 4 weeks.
Study: NCT00302822
Drug: enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: from week 0 to 24
Study: NCT00302822
Drug: emtricitabine/tenofovir
Normalized name: EMTRICITABINE/TENOFOVIR
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 pill/day
Study: NCT00302822
Drug: lopinavir or efavirenz
Normalized name: Lopinavir
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: investigator choice
Study: NCT04414943
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For women in this group, active drug (s-ketamine 0.2 mg/kg in 20 ml normal saline) will be infused at a rate of 30 ml/h (infusion finished in 40 minutes) after giving birth. They will be monitored for 60 minutes and then sent back to the ward.
Study: NCT01303055
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 25 mg, tablets, orally, once daily : two years
Study: NCT01303055
Drug: Metformin 750 mg
Normalized name: metFORMIN 750 mg oral tablet, extended release
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 750 mg, tablets, orally, thrice daily: two years~The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %.
Study: NCT00203606
Drug: pegylated interferon alfa-2a ( Roche) and ribavirin
Normalized name: Pegylated-interferon alfa 2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegylated interferon alfa-2a ( Roche) and ribavirin
Study: NCT03033784
Drug: 8 International Units (IU) of Oxytocin
Normalized name: oxytocin 5 UNT/ML
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive one dose of intranasal oxytocin at a dose of 8IU.